Altay Therapeutics, RADD Pharmaceuticals, Rubik Therapeutics, VastBiome and Waypoint Bio to receive free year of lab bench use and other amenities at prominent bioscience incubators Bristol Myers Squibb Company today announced five innovative biotech startups as winners of the company’s 2021 Golden Ticket Contests. The winners are: RADD Pharmaceuticals and Rubik Therapeutics Waypoint Bio and Altay Therapeutics and ...

Altay Therapeutics, RADD Pharmaceuticals, Rubik Therapeutics, VastBiome and Waypoint Bio to receive free year of lab bench use and other amenities at prominent bioscience incubators

Bristol Myers Squibb Company (NYSE:BMY) today announced five innovative biotech startups as winners of the company's 2021 Golden Ticket Contests. The winners are: RADD Pharmaceuticals and Rubik Therapeutics (LabCentral, Cambridge, MA), Waypoint Bio (BioLabs@NYULangone, New York, NY) and Altay Therapeutics and VastBiome (MBC BioLabs, San Francisco Bay Area, CA).

"These Golden Tickets are an important way for us to foster growth of life science startup companies and bolster the communities in which we work and live," said Kristen Hege, M.D., Senior Vice President, Early Clinical Development, Hematology/Oncology and Cell Therapy and San Francisco site head. "A core part of our philosophy is to encourage interdisciplinary collaborations and novel approaches. Our goal is that BMS' general support of the three incubators and our specific contribution to companies within them will help spur the next wave of scientific breakthroughs that lead to development of new medicines that improve the lives of people with serious diseases."

Bristol Myers Squibb has annually held the Golden Ticket contest since it began in Cambridge in 2016 for promising biotech start-ups pursuing research in novel target identification, drug delivery, discovery technology platforms or translational R&D in a variety of therapeutic research fields. The Golden Ticket contest provides recipient companies with one year of fully equipped, permitted and supported lab space for biomedical research, plus programming and networking opportunities through these incubators to help advance their science and build their companies.

About This Year's Winning Companies

Altay Therapeutics , founded by Ali Rayet Ozes, Ph.D., and Osman Nidai Ozes, Ph.D., in 2019, is a preclinical-stage drug discovery company that is working to develop therapies by targeting disease-causing transcription factors (TFs).

The company's platform technology enables discovery of small molecule binding sites within intrinsically disordered domains. The company has completed proof-of-concept studies by developing first-in-class inhibitors targeting previously undruggable TFs for the treatment of idiopathic pulmonary fibrosis (IPF), Ewing's Sarcoma, prostate cancer and facioscapulohumeral muscular dystrophy (FSHD). Altay Therapeutics now is testing the efficacy of its compounds by collaborating with world-class experts at Georgetown University, Saint Louis University School of Medicine and University of California San Francisco. Based on insights gained from its platform, the company is targeting numerous other disease-causing TFs to develop more specific therapies and improve the quality of life for larger patient populations.

RADD Pharmaceuticals is focused on previously undrugged cancer targets. The startup is backed by the early-stage venture capital firm Canaan.

Rubik Therapeutics , co-founded by Murray Robinson, Ph.D., in 2021, is on a mission to develop best-in-class engineered cell therapies for solid tumors by leveraging its data-driven discovery platforms. The company is backed by Illumina Accelerator.

VastBiome , founded by Kareem Barghouti, MBA, Kovi Bessoff, M.D., Ph.D., Peter McCaffrey, M.D., and Ayin Vala, M.S., in 2019, is a DNA-first drug discovery company mapping the human gut microbiome to make medicines. The company accesses small molecules produced from the gut and uncovers their function. VastBiome is using proprietary methods in genomic sequencing, artificial intelligence and synthetic biology to discover biomarkers and novel therapeutics for the most challenging immunologic disorders. The company's collaborators include a number of leading institutions such as the Cleveland Clinic, Moffitt Cancer Center and Baylor College of Medicine.

Waypoint Bio , founded by David Phizicky, Ph.D., and Xinchen Wang, Ph.D., in 2021, is a startup working to develop novel approaches to treat dosage-sensitive diseases such as haploinsufficiencies. Waypoint is building a genomics and machine-learning platform for high-throughput screening that can extract high-dimensional multiplexed cellular features. Their platform enables profiling of cellular processes linked to gene dosage that are unobservable by other screening approaches.

About Bristol Myers Squibb

Bristol Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. For more information about Bristol Myers Squibb, visit us at BMS.com or follow us on LinkedIn , Twitter , YouTube , Facebook and Instagram .

Celgene and Juno Therapeutics are wholly owned subsidiaries of Bristol-Myers Squibb Company. In certain countries outside the U.S., due to local laws, Celgene and Juno Therapeutics are referred to as, Celgene, a Bristol Myers Squibb company and Juno Therapeutics, a Bristol Myers Squibb company.

About LabCentral (Cambridge, MA)

A private, non-profit institution, LabCentral was founded in 2013 as a launchpad for high potential life-sciences and biotech startups. Operating a total of 150,000 square-feet in the heart of Kendall Square in Cambridge, Mass., LabCentral offers fully permitted laboratory and office space for as many as 70 startups comprising approximately 500 scientists and entrepreneurs. For more information, visit www.labcentral.org or Twitter .

About BioLabs@NYULangone (New York, NY)

BioLabs New York has partnered with NYU Langone Health to build a unique biotech co-working facility in Manhattan to attract the best companies in early-stage life sciences and help them scale in a fraction of the time it would take a company working out of a traditional co-working space. This is done by providing a collaborative space, top-of-the-line research equipment, business support and acceleration programming. BioLabs@NYULangone helps its residents forge the connections that can take business and science goals to the next level. Its roster of diverse resident companies reap the benefits of an unparalleled location in the heart of Soho and Hudson Square, experienced technical support, a collaborative community and Startup NY Tax free zone.

About MBC BioLabs (San Francisco, CA)

MBC BioLabs is dedicated to helping life-science startups succeed. By renting space as small as a single bench and providing these entrepreneurial scientists with access to millions of dollars of equipment, MBC BioLabs allows companies to be fast, focused, and frugal. It has three sites: one in the Dogpatch neighborhood in San Francisco and two campuses in San Carlos, Calif. Each site has a complete molecular biology core facility that allows companies to do experiments on day one. MBC BioLabs has partnerships with leading pharmaceutical and life-science companies as well as a built-in venture capital firm, Mission BioCapital. These partnerships provide entrepreneurs with valuable insights about where to focus their efforts and accelerates the innovation pipeline. Since opening in 2013, MBC BioLabs has helped launch and grow 230 companies. These companies have brought 54 programs to the clinic, produced 13 approved diagnostics, and raised over $10 billion.

CorporateFinancial_News

Bristol Myers Squibb

Media Inquiries:
media@bms.com

Investors:
Tim Power
609-252-7509
Timothy.Power@bms.com

Nina Goworek
908-673-9711
Nina.Goworek@bms.com

News Provided by Business Wire via QuoteMedia

INVESTOR ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: Class Action Lawsuits filed on behalf of BMY, LSPD, PTON, ZG Investors, Lead Plaintiff Deadlines Set

Kahn Swick & Foti, LLC ("KSF") and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors of pending deadlines in the following securities class action lawsuits:

Bristol-Myers Squibb Company (BMY)
Class: Investors who received Contingent Value Rights ("CVRs") (BMY.RT) in exchange for their shares of Celgene Corporation (CELG) pursuant to Bristol-Myers' acquisition of Celgene on November 20, 2019
Lead Plaintiff Motion Deadline: December 6, 2021
MISLEADING PROSPECTUS
To learn more, visit https://www.ksfcounsel.com/cases/nyse-bmy/

Keep reading... Show less

CLAIMSFILER ALERTS BRISTOL MYERS Investors to Lead Plaintiff Deadline in Class Action Lawsuit Against Bristol-Myers Squibb Company - BMY

- ClaimsFiler, a FREE shareholder information service, reminds investors with losses in excess of $100,000 that they have until December 6, 2021 to file lead plaintiff applications in a securities class action lawsuit against Bristol-Myers Squibb Company ("BMS" or "the Company") (NYSE: BMY), if they received Contingent Value Rights ("CVRs") (NYSE: BMY.RT) in exchange for their shares of Celgene Corporation (NASDAQ: CELG) pursuant to BMS' acquisition of Celgene on November 20, 2019 . This action is pending in the United States District Court for the Southern District of New York .

Get Help
BMS investors should visit us at https://claimsfiler.com/cases/nyse-bmy-3/ or call toll-free (844) 367-9658. Lawyers at Kahn Swick & Foti, LLC are available to discuss your legal options.

Keep reading... Show less
New Research Analysis Shows VINIA Reduces Oxidation Of LDL-Cholesterol To Support Cardiovascular Improved Functioning

New Research Analysis Shows VINIA Reduces Oxidation Of LDL-Cholesterol To Support Cardiovascular Improved Functioning

New research analysis affirms the addition of the following structure function claims for VINIA® according to FDA Guidelines for Dietary Supplements:

  • VINIA® prevents Lipid Oxidation
  • VINIA® protects the body by preventing oxidative damage to the cells
  • VINIA® reduces oxidation of LDL cholesterol

BioHarvest Sciences Inc. (CSE: BHSC) ("BioHarvest" or the "Company") reports that recent research analysis provides additional support for anti-oxidation structurefunction claims of VINIA®. This analysis, when added to the clinical study [1] conducted by the Company, provides a clear substantiation to BioHarvest's claims relating to anti-oxidation, lipid anti-oxidation, and scavenging free radicals.

Keep reading... Show less

Amgen Announces Positive Top-Line Results From Otezla® Phase 3 DISCREET Study In Moderate To Severe Genital Psoriasis

- Amgen (NASDAQ: AMGN) today announced positive top-line results from the DISCREET trial, a Phase 3, multicenter, randomized, placebo-controlled, double-blind study to assess the efficacy of Otezla ® (apremilast) in adults with moderate to severe genital psoriasis and moderate to severe plaque psoriasis. The study showed that oral Otezla 30 mg twice daily achieved a clinically meaningful and statistically significant improvement, compared with placebo, in the primary endpoint of the modified static Physician's Global Assessment of Genitalia (sPGA-G) response (defined as an sPGA-G score of clear (0) or almost clear (1) with at least a 2-point reduction from baseline) at week 16.

In addition, all secondary endpoints were also met with meaningful and significant improvements in Genital Psoriasis Itch Numerical Rating Scale (GPI-NRS) response (defined as at least a 4-point reduction from baseline in GPI-NRS item score within the Genital Psoriasis Symptoms for subjects with a baseline score of ≥ 4); affected body surface area (BSA) change from baseline; Dermatology Life Quality Index (DLQI) change from baseline; and static Physician's Global Assessment (sPGA) response (defined as sPGA score of clear (0) or almost clear (1) with at least a 2-point reduction from baseline) at week 16 with Otezla versus placebo.

Keep reading... Show less

FDA Approves New KYPROLIS® Combination Regimen With DARZALEX FASPRO® and dexamethasone For Patients With Multiple Myeloma At First Or Subsequent Relapse

Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved the expansion of the KYPROLIS ® (carfilzomib) U.S. prescribing information to include its use in combination with DARZALEX FASPRO ® (daratumumab and hyaluronidase-fihj) and dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma who have received one to three lines of therapy.

"I am pleased that the addition of subcutaneous daratumumab to KYPROLIS plus dexamethasone will offer increased flexibility and convenience for patients with relapsed or refractory multiple myeloma and will greatly reduce the administration burden," said David M. Reese , M.D., executive vice president of Research and Development at Amgen.

Keep reading... Show less
Solarvest Web Site Launched in Hong Kong to Service South Easy Asia

Solarvest Web Site Launched in Hong Kong to Service South Easy Asia

(TheNewswire)

Solarvest BioEnergy Inc.

TheNewswire - December 1st 2021 Solarvest BioEnergy Inc. ("Solarvest" or the "Company") (TSXV:SVS)

Keep reading... Show less

Top News

Related News